Omeros Announces First Commercial Sales of YARTEMLEA®

Omeros Corporation (NASDAQ: OMER) today announced that the first commercial shipments of YARTEMLEA® (narsoplimab-wuug) to its ...
MarketWatch

FDA Approves Omeros' YARTEMLEA(R) -- First and Only Therapy Indicated for TA-TMA

The MarketWatch News Department was not involved in the creation of this content. -- Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: ...
Nature

Mannose-Binding Lectin and Its Role in Immune Response

Mannose-binding lectin (MBL) is a critical serum protein of the innate immune system that recognises distinct carbohydrate signatures on pathogens, initiating the lectin pathway of the complement ...
Rutland Herald

Omeros Announces New Date for YARTEMLEA® Approval Conference Call

Omeros Corporation (NASDAQ: OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA ® (narsoplimab-wuug), the first and only therapy indicated for ...
Nasdaq

FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of ...